Edesa Biotech Granted Orphan Drug Designation for Paridiprubart by European Commission
Edesa Biotech announced that the European Commission has granted orphan drug designation to its investigational drug, paridiprubart, for the treatment of Acute Respiratory Distress Syndrome (ARDS).